Checkpoint duo effective against melanoma brain metastases

Among people with melanoma whose tumours have spread to the brain, the combination of nivolumab and ipilimumab produced a complete response in more than a quarter of patients, according to a phase 2 study.

In the open-label, phase 2 US study of 94 volunteers with stage 4 disease with a median follow-up of 14 months, 26% of asymptomatic patients, had complete response

The partial response rate was 30%, and 2% had stable disease for at least six months, according to the results from the CheckMate 204 study funded by Bristol-Myers